NCT04205812 2026-03-31POD1UM-304Incyte CorporationPhase 3 Active not recruiting583 enrolled 22 charts
NCT06103864 2026-03-31A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast CancerAstraZenecaPhase 3 Recruiting625 enrolled
NCT05374512 2026-01-27A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)AstraZenecaPhase 3 Active not recruiting644 enrolled
NCT03734029 2025-10-06Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]Daiichi SankyoPhase 3 Active not recruiting557 enrolled 22 charts 2 FDA
NCT02715804 2020-07-14A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal AdenocarcinomaHalozyme TherapeuticsPhase 3 Terminated492 enrolled 16 charts